Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Medical ProgressArchive

Platelet-Inhibiting Drugs in the Prevention of Clinical Thrombotic Disease — (First of Three Parts)

List of authors.
  • Edward Genton, M.D.,
  • Michael Gent, M.SC.,
  • Jack Hirsh, M.D.,
  • and Laurence A. Harker, M.D.

THE concept of pharmacologic inhibition of platelet reactivity as an approach to antithrombotic therapy has gained considerable support with the recognition of the important role of platelets in thrombus formation, and the identification of drugs that suppress platelet function and retard thrombosis in experimental models.1 2 3 4 5 6 7 8 9 10 11In the selection of drugs for clinical use, it would be valuable to have in vitro laboratory methods to evaluate efficacy and dosage. No such tests are currently available, and it is not known which aspect of platelet function requires suppression to achieve antithrombotic effects.12 In fact, it is likely that . . .

Funding and Disclosures

This review was encouraged by the American Heart Association's Council on Thrombosis.

Author Affiliations

From the Department of Medicine, University of Colorado School of Medicine, Denver, CO, the departments of Pathology, Medicine and Clinical Epidemiology and Biostatistics, McMaster University Medical Centre, Hamilton, ON, Canada, and the Division of Hematology, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, Seattle, WA 98105 (address reprint requests to Dr. Genton at the University of Colorado Medical Center, 4200 E. 9th Ave., Denver, CO 80220).

Print Subscriber? Activate your online access.